Centre for Human Drug Research
Leiden, CL, 2333, Netherlands
NCT Number: NCT02349607
This study will examine the activity of PF-05089771 and pregabalin, alone and in combination on a panel of evoked pain tests carried out from 0.5 to 10 hours following oral dosing in healthy male subjects
Looking for future studies?
Notify Me18 year–55 year
Male
Interventional
Phase 1
Leiden, CL, 2333, Netherlands
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
PF-05089771 300 mg
PF-05089771 300 mg + pregabalin 300 mg
Placeco
pregabalin 300 mg
ibuprofen 600 mg
Time frame: 1-10 hours
Time frame: 1-10 hours
Time frame: 1-10 hours
Time frame: 1-10 hours
Time frame: 1-10 hours
Time frame: 0.5-10
Time frame: 0.5-10
Time frame: 0.5-10
Time frame: 0.5-10 hours
Time frame: 0.5-10 hours
Time frame: 0.5-10 hours
Time frame: 0.5-10 hours
Time frame: 0.5-10 hours
Time frame: 0.5-10 hours
Time frame: 0.5-10 hours
Time frame: 0.5-10 hours
Time frame: 0.5-10 hours
Time frame: 0.5-10 hours
Time frame: 0.5-10 hours
Time frame: 0.5-10 hours
Time frame: 0.5-10 hours
Time frame: 0.5-10 hours
Time frame: 0.5-10 hours
Time frame: 0.5-10 hours
Time frame: 0.5-10 hours
Time frame: 0.5-10 hours
Time frame: 0.5-10 hours
Pfizer
Industry
A Double Blind, Double Dummy, Randomized, Placebo-controlled, 5 Period Cross-over Study To Examine The Effect Of Pf-05089771 Alone And In Combination With Pregabalin On Evoked Pain Endpoints In Healthy Volunteers Using Pregabalin And Ibuprofen As Positive Controls
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsNCT06702423
Healthy
London, United Kingdom
View Trial DetailsNCT07223164
Healthy
Irvine, California, United States
View Trial DetailsNCT05595902
Healthy
Kadıköy, Istanbul, Turkey (Türkiye)
View Trial Details